Navigation Links
ProclaRx to Present on New Bacterial Biofilm Therapies at Biotech Showcase January 11- 13, 2016 in San Francisco
Date:1/5/2016

COLUMBUS, Ohio, Jan. 5, 2016 /PRNewswire/ -- ProclaRx LLC, formerly known as Lattice Biotech LLC, has been selected to speak at the 8th Annual Biotech Showcase on January 11 and the Medtech Showcase, January 12, 2016, regarding their breakthrough medical discovery for treatment of patients with serious bacterial infections.

The Ohio based biotechnology company has developed a technology to break down and destroy biofilms, a physical barrier which protects bacteria and prevents antibiotics and the body's immune system from eradicating chronic infections.

Infections with biofilms are associated with indications as those found in advanced wound care, chronic draining ear infections, and CVID sinusitis. They are highly resistant to antibiotics and have a significant ability to evade normal defenses against bacteria. Recurrent infections and antibiotic resistance is a major clinical and public health problem, with bacterial biofilms implicated in more than 80% of infections.

"The ProclaRx biofilm technology addresses an important unmet medical need that will enable effective treatment for numerous chronic bacterial infections," states Dr. Tom Zupancic, Chief Scientific Officer and co-founder. "Our patented platform technology disrupts the biofilm fortress and enables both the body's immune system and antibiotics to better attack the disease." 

Founded in 2014, ProclaRx has exclusive worldwide rights to develop and commercialize

anti-infective technology from the University of Southern California, Ohio State University and Nationwide Children's Hospital. With $5.5 million invested to-date, they are seeking additional financing and strategic partners. The Biotech Showcase is one of the healthcare industry's largest annual healthcare investor conferences.   

About ProclaRx
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, secretory otitis media and CVID sinusitis. Visit www.proclarx.com or call 949-302-2165 or e-mail info@proclarx.com.

Contact:  Dr. Joseph D. Kittle, Jr.
CEO, ProclaRx
949-302-2165  


'/>"/>
SOURCE ProclaRx
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
3. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
6. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
7. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
8. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
9. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
10. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
11. Amgen To Present At The UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A new tight-tolerance ... and other highly-engineered materials, is being launched by ... has been developed in recent years to service ... and surgical applications. More expensive materials such as ... microextrusion tubing due to their ability to consistently ...
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
(Date:5/2/2017)... Iowa , May 2, 2017  CIVCO ... patient-centric radiotherapy solutions, announced today that Nat ... been with CIVCO since 2012 and has served ... management, senior vice president and general manager, and ... "I am extremely proud of what ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part of ... research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/23/2017)... ... , ... Patients in need of a pulpotomy in Mt. Horeb, ... with or without a referral. Dr. Cotey is a respected dental provider of general ... healthy alternative to a tooth extraction. , When a child has a severely infected ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Today, Our ... Washington, MO with a public ribbon cutting ceremony. Since opening over a ... an alternative to the emergency room. The new Our Urgent Care walk-in clinic ...
(Date:5/22/2017)... ... ... Faithfully following pop culture, people today are forever in pursuit of physical ... programs. It carries on to skin nourished, pampered and nurtured to be soft and ... CDA has found that just like a perfectly cut and polished diamond, that ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... pleased to announce the appointment of James (Jim) Vertino as Chief Information Officer ... a proven, transformational leader who drives innovation and business performance. He defines strategic ...
Breaking Medicine News(10 mins):